ORYZON GENOMICS, S.A. «...678910...» Page 9 out of 13 13/12/2021 08:05 ORYZON GENOMICS, S.A. Other relevant information ORYZON presents new positive efficacy data of iadademstat from the ongoing Phase IIa ALICE clinical trial in acute myeloid leukemia at the ASH-2021 congress. Register number: 13126 12/11/2021 13:28 ORYZON GENOMICS, S.A. Board of Directors Regulations La sociedad remite el reglamento del Consejo de Administración Register number: 12740 12/11/2021 13:27 ORYZON GENOMICS, S.A. General Shareholders’ Meeting Regulations La sociedad remite el Reglamento de la junta general de accionistas Register number: 12738 28/10/2021 17:44 ORYZON GENOMICS, S.A. Other relevant information La sociedad remite información sobre los resultados del tercer trimestre de 2021 Register number: 12445 13/10/2021 08:04 ORYZON GENOMICS, S.A. Other relevant information ORYZON presents safety and efficacy data of vafidemstat from the Phase II SATEEN trial in multiple sclerosis at the ECTRIMS-2021 congress Register number: 12139 29/07/2021 17:51 ORYZON GENOMICS, S.A. Half-yearly financial reports and audit reports/limited audit review La sociedad remite información financiera del primer semestre de 2021 Register number: 11043 13/07/2021 08:07 ORYZON GENOMICS, S.A. Other relevant information ORYZON receives approval from the Spanish Drug Agency to conduct a Phase IIb clinical trial with vafidemstat in schizophrenia patients. Register number: 10576 09/07/2021 08:01 ORYZON GENOMICS, S.A. Other relevant information ORYZON presents preliminary data from vafidemstat’s Phase II trial ESCAPE in CoVID-19 patients at the 31st European Congress of Clinical Microbiology and Infectious Diseases, ECCMID-2021 Register number: 10551 15/06/2021 07:54 ORYZON GENOMICS, S.A. Other relevant information ORYZON receives FDA approval for its IND for PORTICO, a Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder Register number: 9987 11/06/2021 08:06 ORYZON GENOMICS, S.A. Other relevant information ORYZON presents new iadademstat’s ALICE Phase IIa data at EHA-2021, confirming positive and robust efficacy in combination with azacitidine in AML Register number: 9929 Page 9 out of 13 «...678910...»